

## Review Article

# Toxin-Induced and Genetic Animal Models of Parkinson's Disease

**Shin Hisahara and Shun Shimohama**

*Department of Neurology, Sapporo Medical University, South1, West17, chuo-ku, Sapporo 060-8556, Japan*

Correspondence should be addressed to Shun Shimohama, shimoha@sapmed.ac.jp

Received 13 October 2010; Accepted 31 October 2010

Academic Editor: Yuzuru Imai

Copyright © 2011 S. Hisahara and S. Shimohama. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Parkinson's disease (PD) is a common progressive neurodegenerative disorder. The major pathological hallmarks of PD are the selective loss of nigrostriatal dopaminergic neurons and the presence of intraneuronal aggregates termed Lewy bodies (LBs), but the pathophysiological mechanisms are not fully understood. Epidemiologically, environmental neurotoxins such as pesticides are promising candidates for causative factors of PD. Oxidative stress and mitochondrial dysfunction induced by these toxins could contribute to the progression of PD. While most cases of PD are sporadic, specific mutations in genes that cause familial forms of PD have led to provide new insights into its pathogenesis. This paper focuses on animal models of both toxin-induced and genetically determined PD that have provided significant insight for understanding this disease. We also discuss the validity, benefits, and limitations of representative models.

## 1. Introduction

Parkinson's disease (PD) is one of the most common chronic neurodegenerative disorders. It is characterized by a variety of motor (bradykinesia, rigidity, tremor, and postural instability) and nonmotor (autonomic disturbances and psychosis) symptoms. Although it can be diagnosed accurately, no therapeutic strategies can cure or completely block the progression of PD. Pathologically, PD is characterized by the severe loss of dopaminergic (DAergic) neurons in the pars-compacta nigra and the presence of proteinaceous  $\alpha$ -synuclein inclusions, called Lewy bodies (LBs), which are present in neurons of the central nervous system (specific cortical regions, brain stem, and spinal cord), peripheral autonomic nervous system, enteric nervous system (ENS), and cutaneous nerves [1–3]. Similar to other neurodegenerative diseases, such as Alzheimer's disease, age is the major risk factor for PD although 10% of the people with the disease are younger than 45.

Although PD is regarded as a sporadic disorder, remarkably few environmental causes or triggers have been identified [4–6]. Pesticides and herbicides are the most likely candidates for environmental agents associated with the pathogenesis of PD. On the other hand, PD characteristics are seen in a number of familial motor disorders caused

by different genetic factors. Animal models of neurodegenerative diseases, including PD, have in general been quite instructive in understanding their pathogenesis. Ideally, animal models of PD, whether induced by environmental risk factors (neurotoxins) or genetic manipulations, should faithfully reproduce the clinical manifestations (behavioral abnormalities), pathological features, and molecular dysfunctions characterizing the disease. Unfortunately, animal models rarely mimic the etiology, progression, and pathology of PD completely, and in most cases, only partial insight can be gained from these studies. Despite these difficulties, animal models are considered to be very helpful in the development of therapies to treat PD. In this paper, we discuss recently developed neurotoxin-induced and genetic model animals of PD.

## 2. Animal Models of PD Induced by Neurotoxins

PD is currently viewed as a multifactorial disease. Environmental exposures, particularly to pesticides, are thought to be involved in the pathogenesis of sporadic PD. Specifically, the herbicide Paraquat (PQ) and the fungicide Maneb (MB; manganese ethylene-bis-dithiocarbamate) have been associated with the incidence of PD [7, 8]. However, a causal

role for pesticides in the etiology of PD has yet to be definitively established. In animal models, PD-like disorders induced by neurotoxins or other chemical compounds have led to a better understanding of the pathophysiology of PD (Table 1).

### 3. 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP)

In 1979 and 1983, MPTP was initially identified as a strong neurotoxin when heroin addicts accidentally self-administered MPTP and developed an acute form of parkinsonism that was indistinguishable from idiopathic PD [9, 10]. A detailed neuropathological study of MPTP-induced parkinsonism in humans showed severe neuronal degeneration in the substantia nigra and the absence of LBs [11]. The lack of LBs may have reflected the age of the patient and the duration of exposure to MPTP. The tragic results of MPTP poisoning in the heroin addicts led to the development of MPTP-induced rodent and nonhuman primate animal models of PD, which have proved extremely valuable [12–16]. The MPTP-exposed primates show good response to therapy with L-3,4-dihydroxy-L-phenylalanine (L-DOPA) and dopamine (DA) receptor agonists [15, 16]. However, rats are relatively insensitive to MPTP neurotoxicity compared with primates. Rats given MPTP at doses comparable to those used in mice do not show remarkable neurodegeneration [17, 18]. Only high doses of MPTP cause DAergic neurodegeneration in rats, indicating that complete blockade of the DA receptors is required for them to display signs of parkinsonism. Mice, like rats, are also less sensitive to MPTP than primates [19, 20].

This model also shows pathological changes in the ENS, as observed in PD. In PD, gastrointestinal (GI) dysfunction was hypothesized to depend on neuronal degeneration in the ENS that is similar to that seen in the CNS. Recent studies show that the administration of MPTP results in decreased tyrosine hydroxylase- (TH-) positive enteric neurons in mice, indicating that the MPTP model mice should be suitable for understanding the extranigral pathophysiology of PD [21, 22].

### 4. 6-Hydroxy-Dopamine (6-OHDA)

Like MPTP, 6-OHDA is a neurotoxin that has been successfully used in induction animal models of PD. 6-OHDA's strong neurotoxic effects were described by Ungerstedt in 1971, in a study presenting the first example of using a chemical agent to produce an animal model of PD [23]. Since 6-OHDA cannot cross the blood-brain barrier (BBB), systemic administration fails to induce parkinsonism. This induction model requires 6-OHDA to be injected into the substantia nigra, medial forebrain bundle, and striatum [24, 25]. The effects resemble those in the acute MPTP model, causing neuronal death over a brief time course (12 hours to 2-3 days).

Interestingly, the intrastriatal injection of 6-OHDA causes progressive retrograde neuronal degeneration in the

substantia nigra and ventral tegmental complex (ST-VTA) [25–27]. As in PD, DAergic neurons are killed, and the non-DAergic neurons are preserved. However LBs do not form. Typically, 6-OHDA is used as a hemiparkinson model, in which its unilateral injection into the substantia nigra causes asymmetric motor behavior (turning, rotation) when apomorphine, a DAergic receptor agonist, or amphetamine, a dopamine releasing agent, is given systemically. In this model, the quantifiable motor behavior is a major advantage for screening pharmacological screening agents for their effects on the DAergic system and for testing cell replacement therapies [28–30].

### 5. Rotenone

Rotenone is a naturally occurring complex ketone pesticide derived from the roots of *Lonchocarpus* species. It can rapidly cross cellular membranes without the aid of transporters, including the BBB. Rotenone is a strong inhibitor of complex I, which is located at the inner mitochondrial membrane and protrudes into the matrix.

In 2000, Betarbet et al. demonstrated in rats that chronic systemic exposure to rotenone causes many features of PD, including nigrostriatal DAergic degeneration [31]. Importantly, pathological features match those seen in typical PD. For example, many of the degenerating neurons have intracellular inclusions that are morphologically similar to LBs. These inclusions also show immunoreactivity for  $\alpha$ -synuclein and ubiquitin, like true LBs [31, 32]. The rotenone-administered model animals also reproduce all the behavioral and pathological features seen in the typical form of human PD. However, rotenone-injected rats without nigrostriatal DAergic neuronal loss demonstrate the same abnormal motor behaviors as those with such pathological features [32, 33]. This finding suggested that the abnormal behaviors of PD could depend, at least partly, on the damage to non-DAergic neurons in the nigrostriatal area. Furthermore, rotenone exposure also causes the loss of myenteric neurons in the rat [34].

### 6. Paraquat and Maneb

Because of its close structural similarity to 1-methyl-4-phenylpyridinium (MPP<sup>+</sup>, the active metabolite form of MPTP), an herbicide, 1,1'-dimethyl-4,4'-bipyridinium, named paraquat has been suggested as a risk factor for PD [35]. The systemic administration of paraquat to adult mice results in a significant decrease in substantia nigra DAergic neurons, a decline in striatal dopamine nerve terminal density, and a neurobehavioral syndrome characterized by reduced ambulatory activity [36]. These data support the idea that paraquat crosses the BBB to cause destruction of the dopamine neurons in the substantia nigra, like MPP<sup>+</sup> [36]. The prolonged exposure to paraquat leads to a remarkable accumulation of  $\alpha$ -synuclein-like aggregates in neurons of the substantia nigra pars compacta in mice [37]. Chronic exposure to paraquat also reduces the expression of the nicotinic acetylcholine receptor (nAChR) subunit  $\alpha 3/\alpha 6\beta 2^*$

TABLE 1: Representative neurotoxin-induced mammalian models of Parkinson's disease.

Neurotoxin	Behavioral and pathological features	Molecular mechanisms
MPTP	(1) Parkinsonism (akinesia, rigidity, and tremor) with acute onset (2) Relatively less potent in rodents (3) Good response to L-DOPA and DA-agonists (4) Loss of TH-neurons (-fibers) and DA-content in nigrostriatal region (5) Loss of TH-neurons (-fibers) in ENS (6) $\alpha$ -Synuclein-positive inclusions (7) No typical LBs	(1) Easily crosses the BBB (2) Converted to MPP <sup>+</sup> in glial cells (3) Transferred into mitochondria by transporters (4) Inhibits electron transport chain complex I (5) Upregulation of iNOS, NADPH-oxidase, and ROS (6) Microglial activation
6-OHDA	(1) Intracerebral administration (2) Quantifiable locomotor abnormalities (rotation, akinesia) (3) Good response to L-DOPA and DA-agonists (4) Loss of TH-neurons (-fibers) and DA-content in nigrostriatal region (5) No typical LBs	(1) Transferred into mitochondria by transporters (2) Inhibits electron transport chain complex I (3) Microglial activation
Rotenone	(1) Parkinsonism (bradykinesia, fixed posture, and rigidity) (2) Good response to L-DOPA and DA-agonists (3) Loss of TH-neurons (-fibers) and DA-content in nigrostriatal region (4) $\alpha$ -Synuclein-positive inclusions, resemblance to true LBs (5) Loss of myenteric neurons	(1) Easily crosses the BBB (2) Inhibits electron transport chain complex I (3) Upregulation of NADPH-oxidase (4) Microglial activation
Paraquat (+ Maneb)	(1) Parkinsonism similar to that of induced by MPTP (2) Loss of DA-content in nigrostriatal region (3) $\alpha$ -Synuclein-positive inclusions with long exposure	(1) Crosses the BBB by neutral amino acid transporter (2) Inhibits electron transport chain complex I (3) Reduction of nAChR-mediated DA release (4) Inhibits complex III (Maneb)

MPTP: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 6-OHDA: 6-hydroxy-dopamine; L-DOPA: L-3,4-dihydroxy-L-phenylalanine; TH: tyrosine hydroxylase; DA: dopamine; ENS: enteric nervous system; LB: Lewy body; BBB: blood-brain barrier; MPP<sup>+</sup>: 1-methyl-4-phenylpyridinium; iNOS: inducible nitric oxide synthase; ROS: reactive oxygen species; nAChR: nicotinic acetylcholine receptor.

(the asterisk indicates the possible presence of additional subunits). Normally, the activation of both nAChR subtypes stimulates DA release in the striatum [38–40]. The injection of paraquat selectively reduces the  $\alpha 3/\alpha 6\beta 2^*$ -mediated DA release from the striatum in primates [41].

Manganese ethylenebis-dithiocarbamate (Maneb) is an organomanganese fungicide that is broadly used in agriculture and is a putative causative agent for PD. Surprisingly, Thiruchelvam et al. found that the neurotoxic effects of maneb or paraquat on the nigrostriatal DA system in mice are synergistically potentiated in combination [42]. Their report argued that this finding has important implications for the human risk of PD, because the marked geographical overlap in the estimated annual agricultural applications of paraquat and maneb means that people living in these areas may be exposed to the synergistic neurotoxicity of these two agents [42, 43].

## 7. Pathophysiological Mechanisms of DAergic Neurotoxins

All the representative neurotoxin-induced PD models described above show defective mitochondrial function, manifested by the inhibition of mitochondrial complex I

or III. MPTP is a highly lipophilic agent. After its systemic administration, MPTP rapidly crosses the BBB. Once in the brain, MPTP is converted to 1-methyl-4-phenyl-2,3-dihydropyridium (MPDP<sup>+</sup>) in glial cells (astrocytes) and serotonin neurons by monoamine oxidase B (MAO-B) and then spontaneously oxidizes to MPP<sup>+</sup> [44, 45]. Thereafter, MPP<sup>+</sup> is released into the extracellular space. Unlike MPTP, MPP<sup>+</sup> is a polar molecule that cannot freely enter DAergic neurons. Thus, a plasma membrane transport system is required. MPP<sup>+</sup> has a high affinity for dopamine transporter (DAT) as well as for norepinephrine and serotonin transporters [46, 47]. Once inside DAergic neurons, MPP<sup>+</sup> can accumulate in mitochondria and impair mitochondrial respiration by inhibiting complex I in the electron transport chain [44, 48], which induces the generation of reactive oxygen species (ROS). MPP<sup>+</sup> can also bind to vesicular monoamine transporters (VMATs), which help move selected materials into synaptic vesicles containing DA [49]. MPP<sup>+</sup> can also remain in the cytoplasm and interact with cytosolic enzymes [50].

Inducible nitric oxide synthase (iNOS) is also involved in the pathogenesis of MPP<sup>+</sup>-induced parkinsonism in animal models. Increased iNOS has also been found in the substantia nigra of autopsied PD patients, indicating that NO overproduction is a feature of the human disease

[51, 52]. Excess NO could contribute to the formation of free radicals, which could damage DAergic neurons, leading to the development of PD symptoms. Mice null for iNOS show a resistance to neuronal damage by MPTP, and iNOS inhibitors protect against the degeneration of DAergic neurons in MPTP-treated mice [53, 54]. Furthermore, microglial cells can be activated by the formation of free radicals and iNOS-mediated damage, and thereby exacerbate the toxicity of MPTP [55–57]. Finally, MPTP can also upregulate NADPH-oxidase in the substantia nigra of mice [56], which is significant because NADPH-oxidase appears to be ubiquitously expressed in all brain regions and metabolizes molecular oxygen, generating superoxide as a product. In fact, MPTP toxicity is diminished in mice lacking functional NADPH-oxidase, indicating a pivotal role for superoxide ions in the neurotoxicity induced by MPTP [56].

The toxicity of 6-OHDA also involves mechanisms of oxidative stress. 6-OHDA can be taken up by DAergic neurons through DAT [58, 59]. Once transported into neurons, 6-OHDA is oxidized like DA. The oxidized molecule generates free radicals inhibits mitochondrial complex I and produces superoxide and hydroxyl radicals [58, 59]. It is not only toxic to the DAergic neurons but can also induce microglial activation [59].

Like MPTP, the pesticide rotenone is very lipophilic, crosses the BBB, and is distributed evenly throughout the brain [59, 60]. It can enter mitochondria, where it inhibits complex I of the electron transport chain with high affinity [59]. Interestingly, the inhibition of microglial activation by an antibiotic, minocycline, can attenuate the neurotoxicity of rotenone [61]. Gao et al. also showed that the neurotoxicity of rotenone is reduced in neuron-glia cocultures from NADPH oxidase-null mice [62]. The DA uptake of the neuron-enriched cultures was not affected by the addition of microglia from NADPH oxidase-null mice, the addition of microglia from wild-type (WT) mice significantly increased the sensitivity of DAergic neurons either from WT or knockout (KO) mice to rotenone neurotoxicity. These data indicate that microglial NADPH oxidase, but not neuronal NADPH oxidase, is responsible for the NADPH oxidase-mediated neurotoxicity of rotenone [62]. Paraquat mainly crosses the BBB through the neutral amino acid transporter [63–65]. Once in the brain, it is selectively taken up by the terminals of DA-containing neurons in the substantia nigra by the DAT, and it inhibits mitochondrial complex I [63]. Maneb contains a major active fungicidal component, manganese ethylene-bis-dithiocarbamate (Mn-EBDC). In a rat model in which Mn-EBDC is directly delivered to the lateral ventricles, Mn-EBDC causes selective DAergic neurodegeneration [66]. Mn-EBDC preferentially inhibits mitochondrial complex III [66].

## 8. Genetic Animal Models of PD

Although the etiopathogenesis (including environmental factors) of PD is not fully understood, the extensive examination of human postmortem material, the genetic analysis of patients, and the study of experimental animal models

have shed significant light on the molecular mechanisms involved in its progression. However, since the number of patients with familial PD is extremely low compared to the number with sporadic PD, genetic studies in affected human families are very difficult. Therefore, the development of animal genetic models for PD is especially important, and such models provide an opportunity not only to investigate the genetic etiology of PD but also to identify new factors that could be invaluable in terms of diagnosis, drug design, and/or therapy [67, 68]. Even invertebrate animals, for example, *Drosophila melanogaster*, are useful models for surveys of human PD. While their numbers of neurons and glia are obviously much smaller than in rodents and primates, *Drosophila* have the same types of neuron-glia systems, and a great number of genes and molecular transduction pathways are conserved between *Drosophila* and humans.

In recent years, several genetic animal models of PD have been reported, including models for autosomal-dominant (AD) inheritance patterns. The genes manipulated in these models include *α-synuclein*, *leucine rich repeat kinase 2 (LRRK2)*, *ubiquitin carboxyl-terminal esterase L1 (UCHL1)*, and *high temperature requirement A2 (HTRA2/Omi)* (Table 2). There are also models of autosomal-recessive (AR) inherited PD, which involve KO or knockdown genes for *parkin*, *DJ-1*, and *phosphatase and tensin homolog- (PTEN-) induced novel kinase 1 (PINK1)* (Table 3). In addition, we will review a PD mouse model deficient in *nuclear receptor-related 1 (Nurr1)*, also named *nuclear receptor subfamily 4, group A, member 2 (NR4A2)*, which is a susceptibility gene for familial PD (Table 2).

**8.1. *α-Synuclein.*** *α-synuclein* was the first gene linked to an AD-type familial PD, called Park1. The identification of an *α-synuclein* mutation in this family revolutionized PD research, since *α-synuclein* is the main component of LBs, which are observed in the sporadic PD brain. This striking result strongly indicates that genetic and sporadic PD may share similar etiologies and that investigating *α-synuclein*-mediated pathogenesis in familial PD could uncover important information about sporadic PD. Three missense mutations of *α-synuclein*, encoding the substitutions A30P, A53T, and E46K, have been identified in familial PD [67–70]. Furthermore, the duplication or triplication of *α-synuclein* is sufficient to cause PD, suggesting that the level of *α-synuclein* expression is a critical determinant of PD progression [71, 72]. Even though no direct relationship between sporadic PD and *α-synuclein* expression has yet been shown, the existence of several polymorphisms in the promoter or 3'-UTR of the *α-synuclein* gene suggests that its expression level might be a risk factor [73–75].

Human *α-synuclein* is an abundant 140-amino acid presynaptic phosphoprotein involved in vesicle handling and neurotransmitter release. Mutations in *α-synuclein* that increase the propensity for misfolding are probably deleterious, because the misfolded forms are toxic, and they induce cell death *in vitro* [76, 77]. Among the variety of abnormal forms that mutant *α-synuclein* can adopt, protofibrils and fibrils seem to be the most toxic [77]. These demonstrations

TABLE 2: Autosomal-dominant PD models.

Gene	Animal	Manipulation	DA neuron loss	LB-like inclusions <sup>1</sup>	DA-responsive motor deficits <sup>2</sup>	References
<i>a-synuclein</i> ( <i>PARK1</i> )	Nematode	Transgenic	Yes <sup>§</sup>	No	Yes	[79, 80]
	Fly	Transgenic	Yes	Yes	Yes	[78]
	Mouse	Transgenic	No	Yes <sup>§</sup> (PrP promoter)	Yes <sup>§</sup> (PDGF $\beta$ promoter)	[81–91]
	Rat	Transgenic	Yes	No	Yes	[92–95]
	Monkey	Transgenic	Yes	No	ND	[96]
<i>UCHL1</i> ( <i>PARK5</i> )	Mouse	Transgenic	Yes	No	Yes	[105, 106]
<i>LRRK2</i> ( <i>PARK8</i> )	Nematode	Transgenic	Yes	ND	ND	[116]
	Fly	Transgenic	Yes	No	Yes	[113–115]
	Mouse	Transgenic	No	No	Yes	[117–119]

DA, dopamine; LB, Lewy body; ND, not determined; PrP, prion; PDGF $\beta$  platelet-derived growth factor  $\beta$ .

<sup>1</sup>LB-like inclusions by definition contain filamentous  $\alpha$ -synuclein.

<sup>2</sup>ND could include some degree of behavioral impairment in spontaneous and locomotor activity and in response to sensory stimulation.

<sup>§</sup>Controversial. The opposite result has also been shown.

TABLE 3: Autosomal-recessive PD models and other causative genes of PD.

Gene	Animal	Manipulation	DA neuron loss	LB-like inclusion <sup>1</sup>	DA-responsive motor deficits <sup>2</sup>	References
<i>Parkin</i> ( <i>PARK2</i> )	Nematode	Knockout	No	No	No	[124]
	Fly	Knockout	Yes	No	Yes	[125, 126]
		Transgenic	Yes	No	Yes	[131, 132]
	Mouse	Knockout	No	No	ND	[127–130]
		Transgenic	Yes	Yes	ND	[133]
<i>PINK1</i> ( <i>PARK6</i> )	Fly	Knockout	Yes	No	Yes	[135, 136]
	Mouse	Knockout	No	No	ND	[137–139]
<i>DJ-1</i> ( <i>PARK7</i> )	Fly	Knockout	Yes	No	Yes	[144–148]
	Mouse	Knockout	No	No	ND	[149–151]
<i>HtrA2/Omi</i> ( <i>PARK13</i> )	Fly	Knockout	No	No	No	[153]
	Mouse	Knockout	No	No	ND	[154, 155]
<i>Nurr1</i> ( <i>NR4A2</i> )	Mouse	Knockout	Yes	No	ND	[158–160]

DA, dopamine; LB, Lewy body; ND, not determined.

<sup>1</sup>LB-like inclusions by definition contain filamentous  $\alpha$ -synuclein.

<sup>2</sup>ND could include some degree of behavioral impairment in spontaneous and locomotor activity and in response to sensory stimulation.

of  $\alpha$ -synuclein toxicity *in vitro* led to the creation and extensive analysis of many  $\alpha$ -synuclein-based animal models of PD.

Although flies (*Drosophila*) and nematodes (*C. elegans*) do not have complex nervous systems compared to vertebrates and do not express endogenous  $\alpha$ -synuclein, they are useful for identifying genetic and pharmacological modifiers of  $\alpha$ -synuclein and its product. In *Drosophila*, the overexpression of WT and mutated (A30P, A53T) human  $\alpha$ -synuclein causes the age-dependent loss of dorsomedial DAergic neurons, an accumulation of LB-like filamentous inclusions with  $\alpha$ -synuclein immunoreactivity, and compromised locomotor activity (climbing ability) [78]. In *C. elegans*,  $\alpha$ -synuclein overexpression leads to accelerated DAergic neuronal loss and motor impairment [79, 80]. However, the neurons of these nematodes do not contain notable synuclein-containing inclusions.

Many different mouse lines that overexpress  $\alpha$ -synuclein under various promoters have been generated in the last ten

years, and most have been described in recent reviews [81–83]. Mice expressing  $\alpha$ -synuclein containing two mutations (A30P + A53T) under the TH promoter show progressive declines in locomotor activity and the loss of substantia nigra neurons and striatal DA content [84, 85]. Similarly, mice overexpressing WT human  $\alpha$ -synuclein under the neuron-specific platelet-derived growth factor  $\beta$  (PDGF $\beta$ ) promoter show reduced TH immunoreactivity and DA content in the striatum and impaired motor performance [86]. Mice overexpressing WT human  $\alpha$ -synuclein under another neuron-specific promoter, Thy1, show strong widespread expression in cortical and subcortical neurons, including the substantia nigra pars compacta, but no glial, spinal, or neuromuscular pathology [87–89]. These mice have an increased sensitivity to mitochondrial damage from low doses of MPTP [89]. Mice in which the mouse prion promoter (mPrP) is used to drive the expression of  $\alpha$ -synuclein A53T show  $\alpha$ -synuclein aggregation, fibrils and truncation,  $\alpha$ -synuclein phosphorylation, ubiquitination, and progressive

age-dependent neurodegeneration, just as in humans [90, 91].

Several viral vectors, primarily lentiviruses and adeno-associated viruses (AAVs), have been used to drive exogenous  $\alpha$ -synuclein. Because viral vector delivery requires stereotactic injections within or near the site of the neuronal cell bodies in the substantia nigra pars compacta, rats are generally used for these studies although the model has been reproduced in other rodents [92–95]. The overexpression of human WT or A53T mutant  $\alpha$ -synuclein by AAVs in the SNc neurons of rats causes the progressive age-dependent loss of DA neurons, motor impairment, and  $\alpha$ -synuclein-positive cytoplasmic inclusions [92]. Kirik et al. also overexpressed WT or A53T mutant  $\alpha$ -synuclein in marmosets [96], in which the  $\alpha$ -synuclein protein was expressed in 90%–95% of all substantia nigra DA neurons. The transduced neurons showed evidence of severe pathology, including  $\alpha$ -synuclein-positive cytoplasmic inclusions, granular deposits, and loss of the TH-positivity.

It is particularly notable that the phenotypic outcome of  $\alpha$ -synuclein overexpression in mice heavily depends on the promoter used to drive transgene expression. Unfortunately, most of these models fail to accurately mimic PD in that there is no progressive loss of DA neurons. The loss of TH-positive cell bodies in the substantia nigra does not necessarily indicate cell death. Despite the lack of overt degenerative pathology in the DA-positive neurons, obvious locomotor abnormalities due to degeneration of the nigrostriatal system and a lack of DA responsiveness are observed in the various mouse  $\alpha$ -synuclein models. Thus, most of these lines are excellent models of  $\alpha$ -synuclein-induced neurodegenerative disorders, such as PD.

Although mutated  $\alpha$ -synuclein causes human familial PD,  $\alpha$ -synuclein's physiological roles in PD are not fully understood. In KO mice of  $\alpha$ -synuclein, neuronal development and the formation of presynaptic terminals are normal [97]. Moreover, double KO mice that lack  $\alpha$ - and  $\beta$ -synuclein exhibit normal basic brain functions and survive to adulthood [98]. Thus, the loss of  $\alpha$ -synuclein function is unlikely to play a role in the pathogenesis of  $\alpha$ -synuclein-induced neurodegeneration. Meanwhile,  $\alpha$ -synuclein KO mice show reduced rearing activity in the open field, decreased DA content in the striatum, and a decrease in the reserve pool of vesicles in the hippocampus [97, 99]. These results indicate that  $\alpha$ -synuclein may play a regulatory role *in vivo*, possibly in the fine tuning of synaptic plasticity and/or vesicle maintenance. Interestingly, several lines of  $\alpha$ -synuclein-null mice have a complete or partial resistance to the MPTP [100, 101]. Dauer et al. showed that this resistance is not due to abnormalities of the DA transporter, which appears to function normally in  $\alpha$ -synuclein null mice [100]. These reports indicate that  $\alpha$ -synuclein is not obligatorily coupled to MPTP sensitivity, but can influence MPTP toxicity on some genetic background.

**8.2. UCHL1.** A rare AD-inherited form of PD, PARK5, is caused by a missense mutation in the *UCHL1* gene. *UCHL1* constitutes 1%–2% of the brain proteins and functions

in the ubiquitin-proteasome system. The ubiquitin hydrolase activity of *UCHL1* is important for freeing reusable ubiquitin monomers. The missense mutation in PARK5 causes an Ile93Met substitution in the *UCHL1* protein (*UCHL1*Ile93Met), and this mutant was initially shown to have decreased ubiquitin hydrolase activity [102]. Interestingly, *UCHL1* is detected in LBs in sporadic PD cases [103]. These findings initiated a debate on whether the Ile93Met mutation causes a gain of function (toxicity) or loss of function (deficiency).

The gracile axonal dystrophy (*gad*) mouse is an AR-mutant that shows sensory ataxia at an early stage, followed by motor ataxia. Saigoh et al. showed that these mice exhibit spontaneous intragenic deletion of the *UCHL1* gene and do not express the *UCHL1* protein [104]. These mice do not show obvious pathological changes in the nigrostriatal DA pathway; in particular, there is no loss of DA cell bodies in the substantia nigra. Setsuie et al. generated *UCHL1*Ile93Met-overexpressing mice and reported a reduction in the DAergic neurons of the substantia nigra and of the DA content in the striatum [105]. These mice show behavioral and pathological phenotypes of parkinsonism at 20 weeks of age. Moreover, recently, Yasuda et al. performed a viral vector-mediated  $\alpha$ -synuclein injection into the substantia nigra of the *UCHL1*Ile93Met transgenic mice [106]. These mice show a significantly enhanced loss of DA-positive cell bodies in the substantia nigra and of DA content in the striatum. The neurotoxicity is enhanced by PARK5-associated *UCHL1*Ile93Met mutant, but not influenced by the loss of *UCHL1* WT protein *in vivo*, indicating that the *UCHL1*Ile93Met toxicity results from a gain of function.

**8.3. LRRK2.** The *LRRK2* mutation is another type of AD-PD, called *PARK8*. *LRRK2* is a large protein containing a serine/threonine kinase and a GTPase domain that is localized to membranous structures [107]. The frequency of the common *LRRK2* Gly2019Ser mutation was 1% in patients with sporadic PD and, interestingly, 4% of patients with hereditary PD [108]. The risk of PD when the *LRRK2* Gly2019Ser mutation was present was 28% at age 59 years, 51% at 69 years, and 74% at 79 years. The motor symptoms and non-motor symptoms of *LRRK2*-associated PD are more benign than those of idiopathic PD. In autopsied tissue, the LB pathology was present in a representative *LRRK2* G2019S case, indicating that *LRRK2* and  $\alpha$ -synuclein share some pathogenic mechanisms [109]. Yet, *LRRK2* may play a role in neuronal outgrowth and guidance, and its precise physiological function remains to be clarified [110].

*dLRRK* is a *Drosophila* orthologue of *LRRK2*, and it shows elevated expression in DA neurons of the head [111, 112]. Liu et al. overexpressed constructs with mutations similar to those found in patients (G2019S), in *Drosophila* [113]. The neuronal expression of *LRRK2* or *LRRK2*-G2019S produces an adult-onset selective loss of DAergic neurons, locomotor dysfunction, and early mortality. However, the phenotype caused by the G2019S-*LRRK2* mutant is more severe than that caused by the expression of equivalent levels of WT *LRRK2*. Treatment with L-DOPA improves

the mutant LRRK2-induced locomotor impairment but does not prevent the loss of TH-positive neurons. Some fly models that overexpress other LRRK2 mutations, such as I1122V, Y1699C, and I2020T, show similar results, in terms of an age-dependent impairment of locomotor activity that improves with DA stimulation, and the loss of DA neurons [113–115]. Moreover, in transgenic *C. elegans*, DA marker loss is greater in those expressing G2019S LRRK2 than WT LRRK2 [116].

Transgenic mice made using bacterial artificial chromosome (BAC) technology and expressing WT LRRK2, or the R1441G or G2091S mutation exhibit mild axonal pathology in the nigrostriatal DA projection [117, 118]. However, the conditional overexpression of neither WT LRRK2 nor its G2019S mutation causes degeneration of the DA-containing neurons [119]. Interestingly, although the LRRK2 conditional transgenic mice show minimal nigrostriatal pathologies, they exhibit a progressive age-dependent motor impairment that is improved by DA stimulation. LRRK2 involvement in the pathogenesis of PD may be limited, and other genetic and/or environmental factors are probably required to trigger DA neuronal degeneration.

LRRK2 KO mice are viable, have no major abnormalities, and live to adulthood, and there is no significant difference in the susceptibility of LRRK2-deficient and WT mice to MPTP [120]. In LRRK2-KO *Drosophila* models, differing results on the pathology of the DA neurons have been obtained [111, 121]. Lee et al. showed that LRRK loss-of-function mutants exhibited severely impaired locomotive activity [111]. Moreover, DAergic neurons in LRRK mutants showed a severe reduction in tyrosine hydroxylase immunostaining and shrunken morphology. Conversely, Wang et al. demonstrated that mutants lacking *dLRRK* kinase activity are viable with normal development and life span as well as unchanged number and pattern of DAergic neurons [121]. Nematode deletion mutants indicate that LRRK2 is dispensable for the development and maintenance of DA neurons [122].

**8.4. *Parkin*.** *Parkin* covers approximately 1.3 Mb of genomic DNA and is the causative gene for representative AR juvenile PD (*PARK2*). Mutations in *parkin* are not only a cause of familial PD but are also seen in 20% of young-onset sporadic PD cases [123]. *Parkin* is an E3 ubiquitin ligase that functions in the ubiquitin-proteasome system. The loss of *parkin* function is believed to result in abnormal accumulations of *parkin*'s substrates. Springer et al. demonstrated that *pdr-1* (the nematode *parkin* homolog) mutants are viable and display no obvious morphological defects or alterations in motility, egg-laying behavior, brood size, or life span under standard growth conditions [124]. Moreover, the authors did not detect any effect of the mutations on the survival of the DA neurons in the worms. However, overexpression of the  $\alpha$ -synuclein A53T mutation in *pdr-1* mutants leads to developmental arrest and lethality, indicating this *C. elegans* model recapitulates *parkin* insolubility and aggregation similar to several AR juvenile PD-linked *parkin* mutations [124].

*Drosophila* *parkin*-null mutants exhibit a reduced lifespan, locomotor defects (flight and climbing abilities), and

male sterility [125, 126]. The locomotor defects derive from the apoptotic cell death of muscle subsets whereas the male sterile phenotype derives from a spermatid individualization defect at a late stage of spermatogenesis. Mitochondrial pathology is the earliest manifestation of muscle degeneration and a prominent characteristic of individualizing spermatids in *parkin* mutants. These mutants also display a decrement in the TH level and degeneration of a subset of DA neurons in the brain [126]. Several *parkin*-null mice have been generated and display motor and cognitive deficits including reduced locomotor activity and decreased spontaneous alteration in the T-maze; however, they show no substantial DAergic behavioral abnormalities [127–130]. Pathologically, KO mice exhibit slightly abnormal DA nigrostriatal and locus coeruleus noradrenergic regions [128, 129].

The overexpression of human mutant *parkin* in *Drosophila* causes an age-dependent, selective degeneration of DA neurons accompanied by progressive motor impairment [131, 132]. *Parkin-Q311X* mice also exhibit multiple late-onset and progressive hypokinetic motor deficits [133]. Stereological analyses revealed that the mutant mice develop age-dependent DA neuron degeneration in the substantia nigra and a significant reduction of the striatal DA level, accompanied by a significant loss of DA neuron terminals in the striatum. These results indicate that *parkin* mutants may play a pivotal role in the dominant-negative etiological mechanisms of PD.

**8.5. *PINK1*.** *PINK1* is another causative gene for the AR inherited PD called *PARK6*. *PARK6* is the second most frequent early-onset AR PD. *PINK1* is located in mitochondria and is a putative mitochondrial kinase, because it contains a conserved serine/threonine kinase domain with an N-terminal mitochondrial-targeting motif [134]. Thus, the PD-causative mutations of *PINK1* may cause loss of function. Park et al. and Clark et al. generated and characterized loss-of-function *Drosophila* *PINK1* mutants [135, 136]. These flies exhibit male sterility, apoptotic muscle degeneration, defects in mitochondrial morphology, and increased sensitivity to multiple stresses, including oxidative stress.

Park et al. showed an age-dependent decrease in DA levels and a mild loss of DA neurons in these *Drosophila* mutants [135]. Notably, the *PINK1* mutants share marked phenotypic similarities with *parkin* mutants. *Parkin* overexpression is able to rescue the mitochondrial defects found in *PINK1*, although the double mutants do not show an enhanced phenotype. *PINK1* overexpression does not rescue *parkin* phenotypes. Together, the data indicate that *parkin* and *PINK1* function, at least partly, in a common pathway, and *PINK1* acts upstream of *parkin*. Whereas *PINK1*-deficient mice show age-dependent mitochondrial dysfunction, increased sensitivity to oxidative stress, decreased evoked DA release, and DA receptor agonist-responsive impairment of striatal plasticity, the number of DA neurons, the level of striatal DA, and the level of DA receptors are the same as in WT animals [137–139]. These phenotypes are similar to those of *parkin*-KO mice.

8.6. *DJ-1*. Deletion or point mutations in *DJ-1* have been identified in early onset AR PD (*PARK7*). *DJ-1* plays a role as an antioxidant and chaperone, and it is expressed ubiquitously in the cytosol, mitochondrial matrix, and intermembranous space [140]. In vitro, downregulation or KO of the endogenous *DJ-1* increases cells' vulnerability to oxidative stress and proteasome inhibition, implicating it in the cellular response to oxidative stress [141–143]. *Drosophila* possesses two different orthologs of the human *DJ-1* gene, named *DJ-1 $\alpha$*  and *DJ-1 $\beta$* . While loss-of-function *DJ-1 $\beta$*  mutants have normal numbers of DA neurons, classical genetic analyses and RNAi experiments have yielded contradictory results regarding the function of *DJ-1 $\alpha$*  in DA neuron maintenance [144–148]. However, DA neuron loss cannot be detected in *DJ-1 $\alpha$ /DJ-1 $\beta$*  double-deletion mutants, which are also viable, fertile, and have a normal life span. Some studies have reported a loss of DA neurons upon acute RNA silencing of *DJ-1 $\alpha$*  [147, 148].

Similar to  $\alpha$ -synuclein and parkin KO mice, *DJ-1* KO mice do not show major DA-agonist-responsive behavioral abnormalities or the loss of nigrostriatal DA neurons [149–151]. In particular, although the levels of striatal DA and DA receptors are unchanged, the evoked dopamine release from striatal slices is clearly reduced, most likely as a consequence of increased reuptake. *DJ-1* mutant mice also show an increased sensitivity to MPTP [150]. This is rescued by restoring the *DJ-1* expression in mutant mice, further indicating a role for *DJ-1* in the oxidative stress response.

8.7. *HtrA2/Omi*. *HtrA2/Omi* has been identified as the causative gene for a rare inherited PD, *PARK13*. *HtrA2/Omi* has a PDZ domain in addition to a serine protease domain and is localized to the mitochondrial intermembrane space by its mitochondria-targeting sequence. Whitworth et al. have demonstrated a genetic interaction between *HtrA2/Omi* and *PINK1*, described below, by investigating the eye phenotype of double mutant flies [152]. Their study revealed that *HtrA2/Omi* acts downstream of *PINK1* and is independent of the *parkin* gene. Yet, Yun et al. indicated that *HtrA2/Omi* null fly mutants show neither mitochondrial morphological defects nor DAergic neuronal loss [153]. They also generated a *Drosophila HtrA2/Omi* mutant analogue to the human mutation G399S, which was identified in *PARK13* patients. *HtrA2/Omi* G399S retains a significant, if not complete, function of *HtrA2/Omi*, compared with protease-compromised versions of the protein, indicating that *HtrA2/Omi* is unlikely to play a pivotal role in PD pathogenesis or as an etiological factor. The targeted deletion of *HtrA2/Omi* in mice increases their sensitivity to stress-induced cell death [154, 155]. Animals lacking *HtrA2/Omi* display a progressive movement disorder similar to progressive akinesia, a rigidity syndrome, showing lack of coordination, decreased mobility, bent posture, tremor, and a decreased number of TH-positive striatal neurons [155].

8.8. *Nurr1* (*NR4A2*). *Nurr1* is a member of the nuclear receptor superfamily and is involved in the differentiation and development of nigrostriatal DA neurons. Le et al.

identified two mutations in *Nurr1* associated with Parkinson disease (–291Tdel and –245T → G), which map to the first exon of *NR4A2* and affected one allele in 10 of 107 individuals with familial Parkinson disease [156]. Mutations in *Nurr1* alter the transcription of *TH* and the DA transporter, suggesting that alterations in *Nurr1* may cause chronic DA alterations that could increase susceptibility to PD [157]. *Nurr1* is essential for the development of the ventral mesencephalic DA neurons, because homozygous *Nurr1*-KO mice do not develop DA neurons in the substantia nigra and die soon after birth [158]. Heterozygous *Nurr1*-KO mice exhibit a significant decrease in rotarod performance and locomotor activities [159]. These phenotypes are associated with decreased DA levels in the striatum, decreased numbers of DAergic neurons, and a reduced expression of *Nurr1* and *DAT* in the substantia nigra. Moreover, Le et al. reported that heterozygous *Nurr1*-KO mice show a significant decrease in the total number of TH-positive neurons in the substantia nigra and reduced DA in the striatum after MPTP administration [160]. Thus, these mice show a progressive DA phenotype that bears some resemblance to that found in  $\alpha$ -synuclein-overexpressing and mutant mice. Therefore, *Nurr1*-knockdown mice may provide a good model for investigating the later stages of PD characterized by severe DA neuron loss.

## 9. Concluding Remarks

The symptoms of PD become apparent after more than 80% of the DA neurons have died. The rate of substantia nigral cell loss is assumed to be about 2,500 per year in normal people. The loss of DA function can be accelerated by exposure to neurotoxins and by molecular (genetic) abnormalities, leading to a fast and significant decrease in the number of DA neurons. Consequently, these pharmacological and/or genetic insults can cause early onset of PD. This scenario indicates that critical pathological changes could be initiated one or two decades prior to the onset of PD.

As described above, whether the causative factor is a toxic compound or a mutated gene, we have no perfect animal models of PD. So far, the neurotoxin-induced vertebrate models of PD are suitable for investigating disease-modifying therapies, since they have already proved predictive. Several genetic animal models of PD are useful for understanding the early processes of degeneration in the nigrostriatal DA system. In particular, transgenic  $\alpha$ -synuclein animals are valuable for researching general toxicity effects and the mechanisms of  $\alpha$ -synuclein pathology, as well as for confirming potential therapeutic strategies. Recently, causative mutations and risk factors for PD have been identified in more genes. The homozygous loss of function of *glucocerebrosidase* (*GBA*) causes Gaucher's disease whereas its heterozygous loss of function increases the risk of developing sporadic PD [161]. *ATP13A2* is causative for a juvenile onset AR hereditary PD with dementia (*PARK9*) [162]. Animal models of these mutations have not been described, but once they are available, they will undoubtedly shed new light on the mechanisms of PD.



## Conflict of Interests

The authors declare no conflict of interest.

## References

- [1] H. Braak, R. A. I. de Vos, J. Bohl, and K. Del Tredici, "Gastric  $\alpha$ -synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology," *Neuroscience Letters*, vol. 396, no. 1, pp. 67–72, 2006.
- [2] M. Ikemura, Y. Saito, R. Sengoku et al., "Lewy body pathology involves cutaneous nerves," *Journal of Neuropathology and Experimental Neurology*, vol. 67, no. 10, pp. 945–953, 2008.
- [3] T. Lebouvier, T. Chaumette, S. Paillusson et al., "The second brain and Parkinson's disease," *European Journal of Neuroscience*, vol. 30, no. 5, pp. 735–741, 2009.
- [4] C. M. Tanner, "Is the cause of Parkinson's disease environmental or hereditary? Evidence from twin studies," *Advances in neurology*, vol. 91, pp. 133–142, 2003.
- [5] K. S. M. Taylor, C. E. Counsell, J. C. Gordon, and C. E. Harris, "Screening for undiagnosed parkinsonism among older people in general practice," *Age and Ageing*, vol. 34, no. 5, pp. 501–504, 2005.
- [6] F. D. Dick, G. De Palma, A. Ahmadi et al., "Environmental risk factors for Parkinson's disease and parkinsonism: the Geoparkinson study," *Occupational and Environmental Medicine*, vol. 64, no. 10, pp. 666–672, 2007.
- [7] A. Ascherio, H. Chen, M. G. Weisskopf et al., "Pesticide exposure and risk for Parkinson's disease," *Annals of Neurology*, vol. 60, no. 2, pp. 197–203, 2006.
- [8] H. B. Ferraz, P. H. F. Bertolucci, J. S. Pereira, J. G. C. Lima, and L. A. F. Andrade, "Chronic exposure to the fungicide maneb may produce symptoms and signs of CNS manganese intoxication," *Neurology*, vol. 38, no. 4, pp. 550–553, 1988.
- [9] G. C. Davis, A. C. Williams, and S. P. Markey, "Chronic parkinsonism secondary to intravenous injection of meperidine analogues," *Psychiatry Research*, vol. 1, no. 3, pp. 249–254, 1979.
- [10] J. W. Langston, P. Ballard, J. W. Tetrud, and I. Irwin, "Chronic parkinsonism in humans due to a product of meperidine-analog synthesis," *Science*, vol. 219, no. 4587, pp. 979–980, 1983.
- [11] J. W. Langston, L. S. Forno, J. Tetrud, A. G. Reeves, J. A. Kaplan, and D. Karluk, "Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure," *Annals of Neurology*, vol. 46, no. 4, pp. 598–605, 1999.
- [12] C. C. Chiueh, S. P. Markey, and R. S. Burns, "Neurochemical and behavioral effects of 1-methyl-4-phenyl-1,2,3-tetrahydropyridine (MPTP) in rat, guinea pig, and monkey," *Psychopharmacology Bulletin*, vol. 20, no. 3, pp. 548–553, 1984.
- [13] J. W. Langston, L. S. Forno, C. S. Rebert, and I. Irwin, "Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) in the squirrel monkey," *Brain Research*, vol. 292, no. 2, pp. 390–394, 1984.
- [14] S. P. Markey, J. N. Johannessen, C. C. Chiueh, R. S. Burns, and M. A. Herkenham, "Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism," *Nature*, vol. 311, no. 5985, pp. 464–466, 1984.
- [15] I. J. Kopin and S. P. Markey, "MPTP toxicity: implications for research in Parkinson's disease," *Annual Review of Neuroscience*, vol. 11, pp. 81–96, 1988.
- [16] J. W. Langston and I. Irwin, "MPTP: current concepts and controversies," *Clinical Neuropharmacology*, vol. 9, no. 6, pp. 485–507, 1986.
- [17] A. Giovanni, B. A. Sieber, R. E. Heikkila, and P. K. Sonsalla, "Studies on species sensitivity to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Part 1: systemic administration," *Journal of Pharmacology and Experimental Therapeutics*, vol. 270, no. 3, pp. 1000–1007, 1994.
- [18] A. Giovanni, P. K. Sonsalla, and R. E. Heikkila, "Studies on species sensitivity to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Part 2: central administration of 1-methyl-4-phenylpyridinium," *Journal of Pharmacology and Experimental Therapeutics*, vol. 270, no. 3, pp. 1008–1014, 1994.
- [19] S. Przedborski, V. Jackson-Lewis, A. B. Naini et al., "The parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a technical review of its utility and safety," *Journal of Neurochemistry*, vol. 76, no. 5, pp. 1265–1274, 2001.
- [20] N. Schmidt and B. Ferger, "Neurochemical findings in the MPTP model of Parkinson's disease," *Journal of Neural Transmission*, vol. 108, no. 11, pp. 1263–1282, 2001.
- [21] G. Anderson, A. R. Noorian, G. Taylor et al., "Loss of enteric dopaminergic neurons and associated changes in colon motility in an MPTP mouse model of Parkinson's disease," *Experimental Neurology*, vol. 207, no. 1, pp. 4–12, 2007.
- [22] G. Natale, O. Kastsushenka, F. Fulceri, S. Ruggieri, A. Paparelli, and F. Fornai, "MPTP-induced parkinsonism extends to a subclass of TH-positive neurons in the gut," *Brain Research*, vol. 1355, pp. 195–206, 2010.
- [23] U. Ungerstedt, "Postsynaptic supersensitivity after 6-hydroxy-dopamine induced degeneration of the nigrostriatal dopamine system," *Acta Physiologica Scandinavica, Supplement*, vol. 367, pp. 69–93, 1971.
- [24] D. A. Perese, J. Ulman, J. Viola, S. E. Ewing, and K. S. Bankiewicz, "A 6-hydroxydopamine-induced selective parkinsonian rat model," *Brain Research*, vol. 494, no. 2, pp. 285–293, 1989.
- [25] S. Przedborski, M. Levivier, H. Jiang et al., "Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by intrastriatal injection of 6-hydroxydopamine," *Neuroscience*, vol. 67, no. 3, pp. 631–647, 1995.
- [26] K. Berger, S. Przedborski, and J. L. Cadet, "Retrograde degeneration of nigrostriatal neurons induced by intrastriatal 6-hydroxydopamine injection in rats," *Brain Research Bulletin*, vol. 26, no. 2, pp. 301–307, 1991.
- [27] H. Sauer and W. H. Oertel, "Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and immunocytochemical study in the rat," *Neuroscience*, vol. 59, no. 2, pp. 401–415, 1994.
- [28] M. F. Beal, "Experimental models of Parkinson's disease," *Nature Reviews Neuroscience*, vol. 2, no. 5, pp. 325–334, 2001.
- [29] R. Deumens, A. Blokland, and J. Prickaerts, "Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway," *Experimental Neurology*, vol. 175, no. 2, pp. 303–317, 2002.
- [30] E. C. Hirsch, G. Höglinger, E. Rousset et al., "Animal models of Parkinson's disease in rodents induced by toxins:

- an update," *Journal of Neural Transmission, Supplement*, no. 65, pp. 89–100, 2003.
- [31] R. Betarbet, T. B. Sherer, G. MacKenzie, M. Garcia-Osuna, A. V. Panov, and J. T. Greenamyre, "Chronic systemic pesticide exposure reproduces features of Parkinson's disease," *Nature Neuroscience*, vol. 3, no. 12, pp. 1301–1306, 2000.
- [32] T. B. Sherer, J. H. Kim, R. Betarbet, and J. T. Greenamyre, "Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and  $\alpha$ -synuclein aggregation," *Experimental Neurology*, vol. 179, no. 1, pp. 9–16, 2003.
- [33] N. Lapointe, M. St-Hilaire, M. G. Martinoli et al., "Rotenone induces non-specific central nervous system and systemic toxicity," *The FASEB Journal*, vol. 18, no. 6, pp. 717–719, 2004.
- [34] R. E. Drolet, J. R. Cannon, L. Montero, and J. T. Greenamyre, "Chronic rotenone exposure reproduces Parkinson's disease gastrointestinal neuropathology," *Neurobiology of Disease*, vol. 36, no. 1, pp. 96–102, 2009.
- [35] D. Di Monte, M. S. Sandy, G. Ekstrom, and M. T. Smith, "Comparative studies on the mechanisms of paraquat and 1-methyl-4-phenylpyridine (MPP<sup>+</sup>) cytotoxicity," *Biochemical and Biophysical Research Communications*, vol. 137, no. 1, pp. 303–309, 1986.
- [36] A. I. Brooks, C. A. Chadwick, H. A. Gelbard, D. A. Cory-Slechta, and H. J. Federoff, "Paraquat elicited neurobehavioral syndrome caused by dopaminergic neuron loss," *Brain Research*, vol. 823, no. 1-2, pp. 1–10, 1999.
- [37] A. B. Manning-Bog, A. L. McCormack, J. Li, V. N. Uversky, A. L. Fink, and D. A. Di Monte, "The herbicide paraquat causes up-regulation and aggregation of  $\alpha$ -synuclein in mice: paraquat and  $\alpha$ -synuclein," *Journal of Biological Chemistry*, vol. 277, no. 3, pp. 1641–1644, 2002.
- [38] M. Khwaja, A. McCormack, J. M. McIntosh, D. A. Di Monte, and M. Quik, "Nicotine partially protects against paraquat-induced nigrostriatal damage in mice; link to  $\alpha 6\beta 2^*$  nAChRs," *Journal of Neurochemistry*, vol. 100, no. 1, pp. 180–190, 2007.
- [39] S. Wonnacott, S. Kaiser, A. Mogg, L. Soliakov, and I. W. Jones, "Presynaptic nicotinic receptors modulating dopamine release in the rat striatum," *European Journal of Pharmacology*, vol. 393, no. 1–3, pp. 51–58, 2000.
- [40] S. E. McCallum, N. Parameswaran, T. Bordia, J. M. McIntosh, S. R. Grady, and M. Quik, "Decrease in  $\alpha 3^*/\alpha 6^*$  nicotinic receptors but not nicotine-evoked dopamine release in monkey brain after nigrostriatal damage," *Molecular Pharmacology*, vol. 68, no. 3, pp. 737–746, 2005.
- [41] K. T. O'Leary, N. Parameswaran, L. C. Johnston, J. M. McIntosh, D. A. Di Monte, and M. Quik, "Paraquat exposure reduces nicotinic receptor-evoked dopamine release in monkey striatum," *Journal of Pharmacology and Experimental Therapeutics*, vol. 327, no. 1, pp. 124–129, 2008.
- [42] M. Thiruchelvam, B. J. Brockel, E. K. Richfield, R. B. Baggs, and D. A. Cory-Slechta, "Potentiated and preferential effects of combined paraquat and maneb on nigrostriatal dopamine systems: environmental risk factors for Parkinson's disease?" *Brain Research*, vol. 873, no. 2, pp. 225–234, 2000.
- [43] M. Thiruchelvam, E. K. Richfield, R. B. Baggs, A. W. Tank, and D. A. Cory-Slechta, "The nigrostriatal dopaminergic system as a preferential target of repeated exposures to combined paraquat and maneb: implications for Parkinson's disease," *Journal of Neuroscience*, vol. 20, no. 24, pp. 9207–9214, 2000.
- [44] W. J. Nicklas, I. Vyas, and R. E. Heikkila, "Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine," *Life Sciences*, vol. 36, no. 26, pp. 2503–2508, 1985.
- [45] S. Przedborski and M. Vila, "The 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model: a tool to explore the pathogenesis of Parkinson's disease," *Annals of the New York Academy of Sciences*, vol. 991, pp. 189–198, 2003.
- [46] R. A. Mayer, M. V. Kindt, and R. E. Heikkila, "Prevention of the nigrostriatal toxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by inhibitors of 3,4-dihydroxyphenylethylamine transport," *Journal of Neurochemistry*, vol. 47, no. 4, pp. 1073–1079, 1986.
- [47] E. Bezard, C. E. Gross, M. C. Fournier, S. Dovero, B. Bloch, and M. Jaber, "Absence of MPTP-induced neuronal death in mice lacking the dopamine transporter," *Experimental Neurology*, vol. 155, no. 2, pp. 268–273, 1999.
- [48] R. R. Ramsay and T. P. Singer, "Energy-dependent uptake of N-methyl-4-phenylpyridinium, the neurotoxic metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, by mitochondria," *Journal of Biological Chemistry*, vol. 261, no. 17, pp. 7585–7587, 1986.
- [49] M. Del Zompo, M. P. Piccardi, S. Ruiu, M. Quartu, G. L. Gessa, and A. Vaccari, "Selective MPP<sup>+</sup> uptake into synaptic dopamine vesicles: possible involvement in MPTP neurotoxicity," *British Journal of Pharmacology*, vol. 109, no. 2, pp. 411–414, 1993.
- [50] L. K. Klaidman, J. D. Adams Jr., A. C. Leung, S. S. Kim, and E. Cadenas, "Redox cycling of MPP: evidence for a new mechanism involving hydride transfer with xanthine oxidase, aldehyde dehydrogenase, and lipoamide dehydrogenase," *Free Radical Biology and Medicine*, vol. 15, no. 2, pp. 169–179, 1993.
- [51] S. Hunot, F. Boissière, B. Faucheux et al., "Nitric oxide synthase and neuronal vulnerability in Parkinson's disease," *Neuroscience*, vol. 72, no. 2, pp. 355–363, 1996.
- [52] C. Huerta, E. Sánchez-Ferrero, E. Coto et al., "No association between Parkinson's disease and three polymorphisms in the eNOS, nNOS, and iNOS genes," *Neuroscience Letters*, vol. 413, no. 3, pp. 202–205, 2007.
- [53] G. T. Liberatore, V. Jackson-Lewis, S. Vukosavic et al., "Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease," *Nature Medicine*, vol. 5, no. 12, pp. 1403–1409, 1999.
- [54] T. Dehmer, J. Lindenau, S. Haid, J. Dichgans, and J. B. Schulz, "Deficiency of inducible nitric oxide synthase protects against MPTP toxicity in vivo," *Journal of Neurochemistry*, vol. 74, no. 5, pp. 2213–2216, 2000.
- [55] T. Breidert, J. Callebert, M. T. Heneka, G. Landreth, J. M. Launay, and E. C. Hirsch, "Protective action of the peroxisome proliferator-activated receptor- $\gamma$  agonist pioglitazone in a mouse model of Parkinson's disease," *Journal of Neurochemistry*, vol. 82, no. 3, pp. 615–624, 2002.
- [56] D. C. Wu, V. Jackson-Lewis, M. Vila et al., "Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease," *Journal of Neuroscience*, vol. 22, no. 5, pp. 1763–1771, 2002.
- [57] C. Barcia, A. Sánchez Bahillo, E. Fernández-Villalba et al., "Evidence of active microglia in substantia nigra pars compacta of parkinsonian monkeys 1 year after MPTP exposure," *Glia*, vol. 46, no. 4, pp. 402–409, 2004.

- [58] A. Schober, "Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP," *Cell and Tissue Research*, vol. 318, no. 1, pp. 215–224, 2004.
- [59] J. Bové, D. Prou, C. Perier, and S. Przedborski, "Toxin-induced models of Parkinson's disease," *NeuroRx*, vol. 2, no. 3, pp. 484–494, 2005.
- [60] V. N. Uversky, "Neurotoxicant-induced animal models of Parkinson's disease: understanding the role of rotenone, maneb and paraquat in neurodegeneration," *Cell and Tissue Research*, vol. 318, no. 1, pp. 225–241, 2004.
- [61] M. J. Casarejos, J. Menéndez, R. M. Solano, J. A. Rodríguez-Navarro, J. García De Yébenes, and M. A. Mena, "Susceptibility to rotenone is increased in neurons from parkin null mice and is reduced by minocycline," *Journal of Neurochemistry*, vol. 97, no. 4, pp. 934–946, 2006.
- [62] H. M. Gao, B. Liu, and J. S. Hong, "Critical role for microglial NADPH oxidase in rotenone-induced degeneration of dopaminergic neurons," *Journal of Neuroscience*, vol. 23, no. 15, pp. 6181–6187, 2003.
- [63] K. Shimizu, K. Matsubara, K. Ohtaki, S. Fujimaru, O. Saito, and H. Shiono, "Paraquat induces long-lasting dopamine overflow through the excitotoxic pathway in the striatum of freely moving rats," *Brain Research*, vol. 976, no. 2, pp. 243–252, 2003.
- [64] W. L. Yang and A. Y. Sun, "Paraquat-induced free radical reaction in mouse brain microsomes," *Neurochemical Research*, vol. 23, no. 1, pp. 47–53, 1998.
- [65] A. L. McCormack and D. A. Di Monte, "Effects of L-dopa and other amino acids against paraquat-induced nigrostriatal degeneration," *Journal of Neurochemistry*, vol. 85, no. 1, pp. 82–86, 2003.
- [66] J. Zhang, V. A. Fitsanakis, G. Gu et al., "Manganese ethylenebis-dithiocarbamate and selective dopaminergic neurodegeneration in rat: a link through mitochondrial dysfunction," *Journal of Neurochemistry*, vol. 84, no. 2, pp. 336–346, 2003.
- [67] T. Gasser, "Molecular pathogenesis of Parkinson disease: insights from genetic studies," *Expert Reviews in Molecular Medicine*, vol. 11, p. e22, 2009.
- [68] A. J. Lees, J. Hardy, and T. Revesz, "Parkinson's disease," *The Lancet*, vol. 373, no. 9680, pp. 2055–2066, 2009.
- [69] R. Krüger, W. Kuhn, T. Müller et al., "Ala30Pro mutation in the gene encoding  $\alpha$ -synuclein in Parkinson's disease," *Nature Genetics*, vol. 18, no. 2, pp. 106–108, 1998.
- [70] M. H. Polymeropoulos, C. Lavedan, E. Leroy et al., "Mutation in the  $\alpha$ -synuclein gene identified in families with Parkinson's disease," *Science*, vol. 276, no. 5321, pp. 2045–2047, 1997.
- [71] A. B. Singleton, M. Farrer, J. Johnson et al., " $\alpha$ -Synuclein locus triplication causes Parkinson's disease," *Science*, vol. 302, no. 5646, p. 841, 2003.
- [72] A. B. Singleton, "Altered  $\alpha$ -synuclein homeostasis causing Parkinson's disease: the potential roles of dardarin," *Trends in Neurosciences*, vol. 28, no. 8, pp. 416–421, 2005.
- [73] C. Holzmann, R. Krüger, A. M. M. Vieira Saecker et al., "Polymorphisms of the  $\alpha$ -synuclein promoter: expression analyses and association studies in Parkinson's disease," *Journal of Neural Transmission*, vol. 110, no. 1, pp. 67–76, 2003.
- [74] P. Pals, S. Lincoln, J. Manning et al., " $\alpha$ -Synuclein promoter confers susceptibility to Parkinson's disease," *Annals of Neurology*, vol. 56, no. 4, pp. 591–595, 2004.
- [75] S. Winkler, J. Hagenah, S. Lincoln et al., " $\alpha$ -synuclein and Parkinson disease susceptibility," *Neurology*, vol. 69, no. 18, pp. 1745–1750, 2007.
- [76] M. R. Cookson, "The biochemistry of Parkinson's disease," *Annual Review of Biochemistry*, vol. 74, pp. 29–52, 2005.
- [77] V. M. Y. Lee and J. Q. Trojanowski, "Mechanisms of Parkinson's disease linked to pathological  $\alpha$ -Synuclein: new targets for drug discovery," *Neuron*, vol. 52, no. 1, pp. 33–38, 2006.
- [78] M. B. Feany and W. W. Bender, "A *Drosophila* model of Parkinson's disease," *Nature*, vol. 404, no. 6776, pp. 394–398, 2000.
- [79] M. Lakso, S. Vartiainen, A. M. Moilanen et al., "Dopaminergic neuronal loss and motor deficits in *Caenorhabditis elegans* overexpressing human  $\alpha$ -synuclein," *Journal of Neurochemistry*, vol. 86, no. 1, pp. 165–172, 2003.
- [80] T. Kuwahara, A. Koyama, K. Gengyo-Ando et al., "Familial Parkinson mutant  $\alpha$ -synuclein causes dopamine neuron dysfunction in transgenic *Caenorhabditis elegans*," *Journal of Biological Chemistry*, vol. 281, no. 1, pp. 334–340, 2006.
- [81] P. O. Fernagut and M. F. Chesselet, "Alpha-synuclein and transgenic mouse models," *Neurobiology of Disease*, vol. 17, no. 2, pp. 123–130, 2004.
- [82] S. M. Fleming and M. F. Chesselet, "Behavioral phenotypes and pharmacology in genetic mouse models of Parkinsonism," *Behavioural Pharmacology*, vol. 17, no. 5-6, pp. 383–391, 2006.
- [83] M. F. Chesselet, "In vivo alpha-synuclein overexpression in rodents: a useful model of Parkinson's disease?" *Experimental Neurology*, vol. 209, no. 1, pp. 22–27, 2008.
- [84] E. K. Richfield, M. J. Thiruchelvam, D. A. Cory-Slechta et al., "Behavioral and neurochemical effects of wild-type and mutated human  $\alpha$ -synuclein in transgenic mice," *Experimental Neurology*, vol. 175, no. 1, pp. 35–48, 2002.
- [85] M. J. Thiruchelvam, J. M. Powers, D. A. Cory-Slechta, and E. K. Richfield, "Risk factors for dopaminergic neuron loss in human  $\alpha$ -synuclein transgenic mice," *European Journal of Neuroscience*, vol. 19, no. 4, pp. 845–854, 2004.
- [86] E. Masliah, E. Rockenstein, I. Veinbergs et al., "Dopaminergic loss and inclusion body formation in  $\alpha$ -synuclein mice: implications for neurodegenerative disorders," *Science*, vol. 287, no. 5456, pp. 1265–1269, 2000.
- [87] P. J. Kahle, M. Neumann, L. Ozmen et al., "Selective insolubility of  $\alpha$ -synuclein in human lewy body diseases is recapitulated in a transgenic mouse model," *American Journal of Pathology*, vol. 159, no. 6, pp. 2215–2225, 2001.
- [88] E. Rockenstein, M. Mallory, M. Hashimoto et al., "Differential neuropathological alterations in transgenic mice expressing  $\alpha$ -synuclein from the platelet-derived growth factor and Thy-1 promoters," *Journal of Neuroscience Research*, vol. 68, no. 5, pp. 568–578, 2002.
- [89] D. D. Song, C. W. Shults, A. Sisk, E. Rockenstein, and E. Masliah, "Enhanced substantia nigra mitochondrial pathology in human  $\alpha$ -synuclein transgenic mice after treatment with MPTP," *Experimental Neurology*, vol. 186, no. 2, pp. 158–172, 2004.
- [90] B. I. Giasson, J. E. Duda, S. M. Quinn, B. Zhang, J. Q. Trojanowski, and V. M. Y. Lee, "Neuronal  $\alpha$ -synucleinopathy with severe movement disorder in mice expressing A53T human  $\alpha$ -synuclein," *Neuron*, vol. 34, no. 4, pp. 521–533, 2002.
- [91] M. K. Lee, W. Stirling, Y. Xu et al., "Human  $\alpha$ -synuclein-harboring familial Parkinson's disease-linked Ala-53  $\rightarrow$  Thr mutation causes neurodegenerative disease with  $\alpha$ -synuclein aggregation in transgenic mice," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 99, no. 13, pp. 8968–8973, 2002.

- [92] D. Kirik, C. Rosenblad, C. Burger et al., "Parkinson-like neurodegeneration induced by targeted overexpression of  $\alpha$ -synuclein in the nigrostriatal system," *Journal of Neuroscience*, vol. 22, no. 7, pp. 2780–2791, 2002.
- [93] C. Lo Bianco, J. L. Ridet, B. L. Schneider, N. Déglon, and P. Aebischer, " $\alpha$ -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 99, no. 16, pp. 10813–10818, 2002.
- [94] R. L. Klein, M. A. King, M. E. Hamby, and E. M. Meyer, "Dopaminergic cell loss induced by human A30P  $\alpha$ -synuclein gene transfer to the rat substantia nigra," *Human Gene Therapy*, vol. 13, no. 5, pp. 605–612, 2002.
- [95] E. Lauwers, Z. Debyser, J. Van Dorpe, B. De Strooper, B. Nuttin, and V. Baekelandt, "Neuropathology and neurodegeneration in rodent brain induced by lentiviral vector-mediated overexpression of  $\alpha$ -synuclein," *Brain Pathology*, vol. 13, no. 3, pp. 364–372, 2003.
- [96] D. Kirik, L. E. Annett, C. Burger, N. Muzyczka, R. J. Mandel, and A. Björklund, "Nigrostriatal  $\alpha$ -synucleinopathy induced by viral vector-mediated overexpression of human  $\alpha$ -synuclein: a new primate model of Parkinson's disease," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 100, no. 5, pp. 2884–2889, 2003.
- [97] A. Abeliovich, Y. Schmitz, I. Fariñas et al., "Mice lacking  $\alpha$ -synuclein display functional deficits in the nigrostriatal dopamine system," *Neuron*, vol. 25, no. 1, pp. 239–252, 2000.
- [98] S. Chandra, F. Fornai, H. -B. Kwon et al., "Double-knockout mice for  $\alpha$ - and  $\beta$ -synucleins: effect on synaptic functions," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 101, no. 41, pp. 14966–14971, 2004.
- [99] D. E. Cabin, K. Shimazu, D. Murphy et al., "Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking  $\alpha$ -synuclein," *Journal of Neuroscience*, vol. 22, no. 20, pp. 8797–8807, 2002.
- [100] W. Dauer, N. Kholodilov, M. Vila et al., "Resistance of  $\alpha$ -synuclein null mice to the parkinsonian neurotoxin MPTP," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 99, no. 22, pp. 14524–14529, 2002.
- [101] O. M. Schlüter, F. Fornai, M. G. Alessandri et al., "Role of  $\alpha$ -synuclein in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice," *Neuroscience*, vol. 118, no. 4, pp. 985–1002, 2003.
- [102] E. Leroy, R. Boyer, G. Auburger et al., "The ubiquitin pathway in Parkinson's disease," *Nature*, vol. 395, no. 6701, pp. 451–452, 1998.
- [103] J. Lowe, H. McDermott, M. Landon, R. J. Mayer, and K. D. Wilkinson, "Ubiquitin carboxyl-terminal hydrolase (PGP 9.5) is selectively present in ubiquitinated inclusion bodies characteristic of human neurodegenerative diseases," *Journal of Pathology*, vol. 161, no. 2, pp. 153–160, 1990.
- [104] K. Saigoh, YU. L. Wang, J. G. Suh et al., "Intragenic deletion in the gene encoding ubiquitin carboxy-terminal hydrolase in gad mice," *Nature Genetics*, vol. 23, no. 1, pp. 47–51, 1999.
- [105] R. Setsuie, YU. L. Wang, H. Mochizuki et al., "Dopaminergic neuronal loss in transgenic mice expressing the Parkinson's disease-associated UCH-L1 I93M mutant," *Neurochemistry International*, vol. 50, no. 1, pp. 119–129, 2007.
- [106] T. Yasuda, T. Nihira, Y.-R. Ren et al., "Effects of UCH-L1 on  $\alpha$ -synuclein over-expression mouse model of Parkinson's disease," *Journal of Neurochemistry*, vol. 108, no. 4, pp. 932–944, 2009.
- [107] S. Biskup, D. J. Moore, F. Celsi et al., "Localization of LRRK2 to membranous and vesicular structures in mammalian brain," *Annals of Neurology*, vol. 60, no. 5, pp. 557–569, 2006.
- [108] D. G. Healy, M. Falchi, S. S. O'Sullivan et al., "Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study," *The Lancet Neurology*, vol. 7, no. 7, pp. 583–590, 2008.
- [109] O. A. Ross, M. Toft, A. J. Whittle et al., "Lrrk2 and Lewy body disease," *Annals of Neurology*, vol. 59, no. 2, pp. 388–393, 2006.
- [110] D. MacLeod, J. Dowman, R. Hammond, T. Leete, K. Inoue, and A. Abeliovich, "The familial Parkinsonism gene LRRK2 regulates neurite process morphology," *Neuron*, vol. 52, no. 4, pp. 587–593, 2006.
- [111] S. B. Lee, W. Kim, S. Lee, and J. Chung, "Loss of LRRK2/PARK8 induces degeneration of dopaminergic neurons in *Drosophila*," *Biochemical and Biophysical Research Communications*, vol. 358, no. 2, pp. 534–539, 2007.
- [112] Y. Imai, S. Gehrke, H. Q. Wang et al., "Phosphorylation of 4E-BP by LRRK2 affects the maintenance of dopaminergic neurons in *Drosophila*," *EMBO Journal*, vol. 27, no. 18, pp. 2432–2443, 2008.
- [113] Z. Liu, X. Wang, YI. Yu et al., "A *Drosophila* model for LRRK2-linked parkinsonism," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 105, no. 7, pp. 2693–2698, 2008.
- [114] C. H. Ng, S. Z. S. Mok, C. Koh et al., "Parkin protects against LRRK2 G2019S mutant-induced dopaminergic neurodegeneration in *Drosophila*," *Journal of Neuroscience*, vol. 29, no. 36, pp. 11257–11262, 2009.
- [115] K. Venderova, G. Kabbach, E. Abdel-Messih et al., "Leucine-rich repeat kinase 2 interacts with Parkin, DJ-1 and PINK-1 in a *Drosophila melanogaster* model of Parkinson's disease," *Human Molecular Genetics*, vol. 18, no. 22, pp. 4390–4404, 2009.
- [116] S. Saha, M. D. Guillily, A. Ferree et al., "LRRK2 modulates vulnerability to mitochondrial dysfunction in *Caenorhabditis elegans*," *Journal of Neuroscience*, vol. 29, no. 29, pp. 9210–9218, 2009.
- [117] Y. Li, W. Liu, T. F. Oo et al., "Mutant LRRK2 BAC transgenic mice recapitulate cardinal features of Parkinson's disease," *Nature Neuroscience*, vol. 12, no. 7, pp. 826–828, 2009.
- [118] X. Li, J. C. Patel, J. Wang et al., "Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson's disease mutation G2019S," *Journal of Neuroscience*, vol. 30, no. 5, pp. 1788–1797, 2010.
- [119] X. Lin, L. Parisiadou, X. L. Gu et al., "Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant  $\alpha$ -synuclein," *Neuron*, vol. 64, no. 6, pp. 807–827, 2009.
- [120] E. Andres-Mateos, R. Mejias, M. Sasaki et al., "Unexpected lack of hypersensitivity in LRRK2 knock-out mice to MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine)," *Journal of Neuroscience*, vol. 29, no. 50, pp. 15846–15850, 2009.
- [121] D. Wang, B. Tang, G. Zhao et al., "Dispensable role of *Drosophila* ortholog of LRRK2 kinase activity in survival of dopaminergic neurons," *Molecular Neurodegeneration*, vol. 3, no. 1, article no. 3, 2008.
- [122] A. Sakaguchi-Nakashima, J. Y. Meir, Y. Jin, K. Matsumoto, and N. Hisamoto, "LRK-1, a *C. elegans* PARK8-related kinase, regulates axonal-dendritic polarity of SV proteins," *Current Biology*, vol. 17, no. 7, pp. 592–598, 2007.

- [123] C. B. Lücking, A. Dürr, V. Bonifati et al., "Association between early-onset Parkinson's disease and mutations in the parkin gene," *New England Journal of Medicine*, vol. 342, no. 21, pp. 1560–1567, 2000.
- [124] W. Springer, T. Hoppe, E. Schmidt, and R. Baumeister, "A *Caenorhabditis elegans* Parkin mutant with altered solubility couples  $\alpha$ -synuclein aggregation to proteotoxic stress," *Human Molecular Genetics*, vol. 14, no. 22, pp. 3407–3423, 2005.
- [125] J. C. Greene, A. J. Whitworth, I. Kuo, L. A. Andrews, M. B. Feany, and L. J. Pallanck, "Mitochondrial pathology and apoptotic muscle degeneration in *Drosophila* parkin mutants," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 100, no. 7, pp. 4078–4083, 2003.
- [126] A. J. Whitworth, D. A. Theodore, J. C. Greene, H. Beneš, P. D. Wes, and L. J. Pallanck, "Increased glutathione S-transferase activity rescues dopaminergic neuron loss in a *Drosophila* model of Parkinson's disease," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 102, no. 22, pp. 8024–8029, 2005.
- [127] J. M. Itier, P. Ibáñez, M. A. Mena et al., "Parkin gene inactivation alters behaviour and dopamine neurotransmission in the mouse," *Human Molecular Genetics*, vol. 12, no. 18, pp. 2277–2291, 2003.
- [128] M. S. Goldberg, S. M. Fleming, J. J. Palacino et al., "Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons," *Journal of Biological Chemistry*, vol. 278, no. 44, pp. 43628–43635, 2003.
- [129] R. Von Coelln, B. Thomas, J. M. Savitt et al., "Loss of locus coeruleus neurons and reduced startle in parkin null mice," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 101, no. 29, pp. 10744–10749, 2004.
- [130] F. A. Perez and R. D. Palmiter, "Parkin-deficient mice are not a robust model of parkinsonism," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 102, no. 6, pp. 2174–2179, 2005.
- [131] C. Wang, R. Lu, X. Ouyang et al., "*Drosophila* overexpressing parkin R275W mutant exhibits dopaminergic neuron degeneration and mitochondrial abnormalities," *Journal of Neuroscience*, vol. 27, no. 32, pp. 8563–8570, 2007.
- [132] T. K. Sang, H. Y. Chang, G. M. Lawless et al., "A *Drosophila* model of mutant human parkin-induced toxicity demonstrates selective loss of dopaminergic neurons and dependence on cellular dopamine," *Journal of Neuroscience*, vol. 27, no. 5, pp. 981–992, 2007.
- [133] X. H. Lu, S. M. Fleming, B. Meurers et al., "Bacterial artificial chromosome transgenic mice expressing a truncated mutant parkin exhibit age-dependent hypokinetic motor deficits, dopaminergic neuron degeneration, and accumulation of proteinase k-resistant  $\alpha$ -synuclein," *Journal of Neuroscience*, vol. 29, no. 7, pp. 1962–1976, 2009.
- [134] L. Silvestri, V. Caputo, E. Bellacchio et al., "Mitochondrial import and enzymatic activity of PINK1 mutants associated to recessive parkinsonism," *Human Molecular Genetics*, vol. 14, no. 22, pp. 3477–3492, 2005.
- [135] J. Park, S. B. Lee, S. Lee et al., "Mitochondrial dysfunction in *Drosophila* PINK1 mutants is complemented by parkin," *Nature*, vol. 441, no. 7097, pp. 1157–1161, 2006.
- [136] I. E. Clark, M. W. Dodson, C. Jiang et al., "*Drosophila* pink1 is required for mitochondrial function and interacts genetically with parkin," *Nature*, vol. 441, no. 7097, pp. 1162–1166, 2006.
- [137] T. Kitada, A. Pisani, D. R. Porter et al., "Impaired dopamine release and synaptic plasticity in the striatum of PINK1-deficient mice," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 104, no. 27, pp. 11441–11446, 2007.
- [138] C. A. Gautier, T. Kitada, and J. Shen, "Loss of PINK1 causes mitochondrial functional defects and increased sensitivity to oxidative stress," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 105, no. 32, pp. 11364–11369, 2008.
- [139] S. Gispert, F. Ricciardi, A. Kurz et al., "Parkinson phenotype in aged PINK1-deficient mice is accompanied by progressive mitochondrial dysfunction in absence of neurodegeneration," *PLoS One*, vol. 4, no. 6, Article ID e5777, 2009.
- [140] L. I. Zhang, M. Shimoji, B. Thomas et al., "Mitochondrial localization of the Parkinson's disease related protein DJ-1: implications for pathogenesis," *Human Molecular Genetics*, vol. 14, no. 14, pp. 2063–2073, 2005.
- [141] A. Mitumoto, Y. Nakagawa, A. Takeuchi, K. Okawa, A. Iwamatsu, and Y. Takanezawa, "Oxidized forms of peroxiredoxins and DJ-1 on two-dimensional gels increased in response to sublethal levels of paraquat," *Free Radical Research*, vol. 35, no. 3, pp. 301–310, 2001.
- [142] T. Yokota, K. Sugawara, K. Ito, R. Takahashi, H. Ariga, and H. Mizusawa, "Down regulation of DJ-1 enhances cell death by oxidative stress, ER stress, and proteasome inhibition," *Biochemical and Biophysical Research Communications*, vol. 312, no. 4, pp. 1342–1348, 2003.
- [143] C. Martinat, S. Shendelman, A. Jonason et al., "Sensitivity to oxidative stress in DJ-1-deficient dopamine neurons: An ES-derived cell model of primary Parkinsonism," *PLoS Biology*, vol. 2, no. 11, article e327, 2004.
- [144] M. Meulener, A. J. Whitworth, C. E. Armstrong-Gold et al., "*Drosophila* DJ-1 mutants are selectively sensitive to environmental toxins associated with Parkinson's disease," *Current Biology*, vol. 15, no. 17, pp. 1572–1577, 2005.
- [145] F. M. Menzies, S. C. Yenissetti, and K. T. Min, "Roles of *Drosophila* DJ-1 in survival of dopaminergic neurons and oxidative stress," *Current Biology*, vol. 15, no. 17, pp. 1578–1582, 2005.
- [146] J. Park, S. Y. Kim, G. H. Cha, S. B. Lee, S. Kim, and J. Chung, "*Drosophila* DJ-1 mutants show oxidative stress-sensitive locomotive dysfunction," *Gene*, vol. 361, no. 1-2, pp. 133–139, 2005.
- [147] Y. Yang, S. Gehrke, M. E. Haque et al., "Inactivation of *Drosophila* DJ-1 leads to impairments of oxidative stress response and phosphatidylinositol 3-kinase/Akt signaling," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 102, no. 38, pp. 13670–13675, 2005.
- [148] E. Lavara-Culebras and N. Paricio, "*Drosophila* DJ-1 mutants are sensitive to oxidative stress and show reduced lifespan and motor deficits," *Gene*, vol. 400, no. 1-2, pp. 158–165, 2007.
- [149] M. S. Goldberg, A. Pisani, M. Haburcak et al., "Nigrostriatal dopaminergic deficits and hypokinesia caused by inactivation of the familial parkinsonism-linked gene DJ-1," *Neuron*, vol. 45, no. 4, pp. 489–496, 2005.
- [150] R. H. Kim, P. D. Smith, H. Aleyasin et al., "Hypersensitivity of DJ-1-deficient mice to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and oxidative stress," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 102, no. 14, pp. 5215–5220, 2005.

- [151] E. Andres-Mateos, C. Perier, LI. Zhang et al., "DJ-1 gene deletion reveals that DJ-1 is an atypical peroxiredoxin-like peroxidase," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 104, no. 37, pp. 14807–14812, 2007.
- [152] A. J. Whitworth, J. R. Lee, V. M.-W. Ho, R. Flick, R. Chowdhury, and G. A. McQuibban, "Rhomboid-7 and HtrA2/Omi act in a common pathway with the Parkinson's disease factors Pink1 and Parkin," *DMM Disease Models and Mechanisms*, vol. 1, no. 2-3, pp. 168–174, 2008.
- [153] J. Yun, J. H. Cao, M. W. Dodson et al., "Loss-of-function analysis suggests that Omi/HtrA2 is not an essential component of the pink1/parkin pathway in vivo," *Journal of Neuroscience*, vol. 28, no. 53, pp. 14500–14510, 2008.
- [154] J. M. Jones, P. Datta, S. M. Srinivasula et al., "Loss of Omi mitochondrial protease activity causes the neuromuscular disorder of mnd2 mutant mice," *Nature*, vol. 425, no. 6959, pp. 721–727, 2003.
- [155] L. M. Martins, A. Morrison, K. Klupsch et al., "Neuroprotective role of the reaper-related serine protease HtrA2/Omi revealed by targeted deletion in mice," *Molecular and Cellular Biology*, vol. 24, no. 22, pp. 9848–9862, 2004.
- [156] W. D. Le, P. Xu, J. Jankovic et al., "Mutations in NR4A2 associated with familial Parkinson disease," *Nature Genetics*, vol. 33, no. 1, pp. 85–89, 2003.
- [157] P. Sacchetti, T. R. Mitchell, J. G. Granneman, and M. J. Bannon, "Nurr1 enhances transcription of the human dopamine transporter gene through a novel mechanism," *Journal of Neurochemistry*, vol. 76, no. 5, pp. 1565–1572, 2001.
- [158] R. H. Zetterström, L. Solomin, L. Jansson, B. J. Hoffer, L. Olson, and T. Perlmann, "Dopamine neuron agenesis in Nurr1-deficient mice," *Science*, vol. 276, no. 5310, pp. 248–250, 1997.
- [159] C. Jiang, X. Wan, YI. He, T. Pan, J. Jankovic, and W. Le, "Age-dependent dopaminergic dysfunction in Nurr1 knockout mice," *Experimental Neurology*, vol. 191, no. 1, pp. 154–162, 2005.
- [160] W. D. Le, O. M. Conneely, Y. He, J. Jankovic, and S. H. Appel, "Reduced Nurr1 expression increases the vulnerability of mesencephalic dopamine neurons to MPTP-induced injury," *Journal of Neurochemistry*, vol. 73, no. 5, pp. 2218–2221, 1999.
- [161] O. Goker-Alpan, R. Schiffmann, M. E. LaMarca, R. L. Nussbaum, A. McInerney-Leo, and E. Sidransky, "Parkinsonism among Gaucher disease carriers," *Journal of Medical Genetics*, vol. 41, no. 12, pp. 937–940, 2004.
- [162] A. Ramirez, A. Heimbach, J. Gründemann et al., "Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase," *Nature Genetics*, vol. 38, no. 10, pp. 1184–1191, 2006.